	US 12,419,869 B2
	Methods of treating multiple sclerosis
Allitia DiBernardo, Philadelphia, PA (US); Tatiana Sidorenko, Allschwil (CH); Michel Burcklen, Allschwil (CH); Sivi Ouwerkerk-Mahadevan, Beerse (BE); Andrea Vaclavkova, Allschwil (CH); Brian Patrick Hennessy, Geneva (CH); and Hilke Kracker, Weil am Rhein (DE)
Assigned to Vanda Pharmaceuticals Inc., Washington, DC (US)
Filed by Allitia DiBernardo, Philadelphia, PA (US); Tatiana Sidorenko, Allschwil (CH); Michel Burcklen, Allschwil (CH); Sivi Ouwerkerk-Mahadevan, Beerse (BE); Andrea Vaclavkova, Allschwil (CH); Brian Patrick Hennessy, Geneva (CH); and Hilke Kracker, Weil am Rhein (DE)
Filed on Mar. 12, 2024, as Appl. No. 18/602,836.
Application 18/602,836 is a continuation of application No. 17/962,968, filed on Oct. 10, 2022, granted, now 11,951,097.
Claims priority of provisional application 63/254,369, filed on Oct. 11, 2021.
Prior Publication US 2024/0285590 A1, Aug. 29, 2024
Int. Cl. A61K 31/426 (2006.01); A61K 9/00 (2006.01); A61K 31/138 (2006.01); A61P 25/28 (2006.01)

CPC A61K 31/426 (2013.01) [A61P 25/28 (2018.01); A61K 9/0053 (2013.01); A61K 31/138 (2013.01)]

8 Claims

1. A method for reducing clinical management events before or during treatment of multiple sclerosis in a patient in need thereof, comprising administering ponesimod in an amount and manner that is described in a drug product label for an approved drug product.